1. European Urology Focus
Differences in Trial and Real-world Populations in the Dutch Castration-resistant Prostate Cancer Registry 
Hans M. Westgeest, Carin A. Uyl-de Groot, Reindert J.A. van Moorselaar, Ronald de Wit, Alphonsus C.M. van den Bergh, Jules L.L.M. Coenen, Harrie P. Beerlage, Mathijs P. Hendriks, Monique M.E.M. Bos, Pieter van den Berg, Agnes J. van de Wouw, Roan Spermon, Michiel O. Boerma, Maud M. Geenen, Lidwine W. Tick, Marco B. Polee, Haiko J. Bloemendal, Igor Cordia, Frank P.J. Peters, Aad I. de Vos, Joan van den Bosch, Alphonsus J.M. van den Eertwegh, Winald R. Gerritsen 
European Urology Focus 
DOI: /j.euf
Copyright © 2016 European Association of Urology Terms and Conditions

2. Fig. 1 Flow diagram of the study population.
CRPC=castration-resistant prostate cancer.
European Urology Focus DOI: ( /j.euf )
Copyright © 2016 European Association of Urology Terms and Conditions

3. Fig. 2
Unadjusted overall survival from castration-resistant prostate cancer (CRPC) diagnosis; median overall survival standard care versus trial subgroup 24 months versus 35 months (p<0.001).
European Urology Focus DOI: ( /j.euf )
Copyright © 2016 European Association of Urology Terms and Conditions